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Theevaluationof iolgia markersisrecoiedasnecsrytothefuture oftokcOy ,epideniology, andq Iive
riskassment. Forbio clnmrkestobecm widelyaccepted,theirvaliditymustbeascertained.Thispaperexplores
therangeofconsiderationsthatcomposetheconceptofvalidiBt asitappliestotheevaluationofbioogicalmarkers. Three
broadcategories ofvalidity (meaem ent, internalstudy, andexternal) arediscussed inthecontextofevWaluatingdata
foruseinquantitativerisk at. Frticularattentionisgiventotheimportnceofmeuementvalidityinthecon-
siderationofwhethertousebiologicalmarkersinepidemiologicstudies. Theconceptsdevelopedinthispresentation are
appliedtoexamplesderivedfromtheoccupationalenvironment. Inthefirstexample, measurementofbrominerelease
asamarkerofethylenedibromidetoxicityisshowntobeoflimiteduseinconstructnganaccuratequantitative assess-
mentoftheriskofdevelopingcancerasaresltoflong-term, low-levelexposure. Thisexampleiscomparedtodataob-
tainedfromstudiesofethyleneade, inwhichhemoglobinalkylationisshowntobeavalidmarkerofbothexposureand
effect.
Introduction
Itisgenerallyacceptedthatvalidbiologicalmarkers canmake
an important contribution to toxicologic and epidemiologic
research, andultimately, toquantitative risk assessment (1-3).
Whileobeisanceispaidtotheconceptofvalidity, littleattention
hasbeengiven towhatit meansandhow toevaluate it. Theob-
jectiveofthispaperistoidentifyandexploretherangeofthe con-
ceptofvalidityandtoaddresshowconsiderationsthatcomprise
theconceptofvalidityandtoaddresshowvaliditypertains tothe
use ofbiological markers inquantitative risk assessment. The
term "biological marker" hasbeendefined as anindicatorthat
signalseventsinbiological systems orsamples, anditisgenerally
taken tobe anybiochemical, genetic, orimmunologic indicator
that canbe measured in abiological specimen (4-7). Ascribed
tothetermbiological markerisitsrole as anindicatorofevents
in acontinuumbetween exposureto axenobioticsubstanceand
resultantdisease(4,6). Biologicmarkers canreferto anyofthree
categories ofevents: exposure, effect, andsusceptibility. Unless
otherwise specified, inthisdiscussion, amarkerisconsidered
torelateto aneventintheexposure-disease continuumwithout
furtherreference astowhetherthateventis exposure, effect, or
susceptibility. Biologicalmarkers cancontributetoquantitative
riskassessment byhelpingto: determinethe formsofdose-time-
response relationships; assess the biologically effective dose;
makeinterspeciescomparisonofeffectivedose, relativepoten-
cy, and effects; resolve the quantitative relationships between
humaninterindividual variability insusceptibility; andidentify
subpopulations that are atenhanced risk(2,8).
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Three broad categories of validity can be distinguished:
measurementvalidity, internal studyvalidity, andexternalvalidi-
ty. Measurementvalidityhasbeendefinedasanexpressionofthe
degreetowhich ".. .ameasurementmeasures whatitpurports
tomeasure" (9). Internalstudyvalidityisthedegreetowhichin-
ferences drawn from a sample are warranted when account is
takenofthe studymethods, therepresentativeness ofthe study
sample, andthenatureofthepopulationfromwhichthesample
isdrawn(9). Externalstudyvalidityistheextenttowhichthefin-
dings ofa study canbegeneralizedtootherpopulations (9).
Biologicalmarkersandthe studiesthatincludethemneedto
be showntohavemeasurement, internal, and external validity
before they can be accurately used in quantitative risk assess-
ment. The use ofinvalid markers can result in nondifferential
misclassifications ofexposure or outcome, which can lead to
underestimationofatrueeffect(3). Riskassessmentsbasedon
studiesthatunderestimateatrueeffectcanleadtoregulationsthat
contain exposure limitsthoughttobe safebut, infact, are not.
Conversely, adifferentialmisclassification bias, depending on
thedirectionofthebias, canlead to regulations containing ex-
posurelimitsthatareeithertoohigh ortoolow. Inquantitative
riskassessment, theinferencesderivedfromsmallstudygroups
aregeneralizedtolargerpopulations. Thestrengthofthose in-
ferencesdependonthemethodologyofthestudy, includingthe
measurements andotherdesign factors thatleadtothe results.
Invalidmeasurements, inferences, orgeneralizationsmay lead
toerroneousriskassessments. Inthispaper, thethreecategories
ofvalidity arediscussedintermsofhowtheyapplytobiological
markers for research and quantitative risk assessment. These
theoreticalconsiderationsofvalidityareillustratedbyexamples
ofriskassessments involvingethylenedibromideandethylene
oxide.SCHULTEANDMAZZUCKELU
Measurement Validity
Measurements are one of the principal building blocks of
quantitative risk assessment. Ifmeasurements areinvalid, itis
likely that the risk assessments constructed from those
measurements will also be invalid. Measurement validity
characterizestheextenttowhich amarkerofaphenomenonhas
contentvalidity (i.e., pertains totheunderlyingphenomenon);
construct validity (i.e., correlates with other relevant
characteristics ofthe underlying phenomenon); and criterion
validity (i.e., predicts some component of the underlying
phenomenon). Ingeneral, thesethreecomponentsofmeasure-
mentvalidity arebestassessed in terms ofthe extent ordegree
towhichtheyapply totheunderlyingphenomenon, ratherthan
as an all-or-none condition (JO).
Content Validity
Contentvalidity istheextenttowhich amarker "incorporates
thedomainofthephenomenonunderstudy" (9). Forexample,
amarkerofinternal dosewillhave contentvalidity ifitreflects
the dose contributed by all routes ofexposure. A markerofef-
fect will have content validity if it encompasses the essential
characteristics ofthe disease it represents. In other words, the
marker mustpertain totheappropriatetargetorgan, oritsrela-
tionship tothenaturalhistoryofthediseaseinquestionmustbe
unambiguous. Forexample, a DNA adductofbenzo(a)pyrene
(BaP) will have content validity as a marker of exposure in a
studyofBaP-inducedlungcancer, sincetheinvolvementofDNA
inBaP-inducedcarcinogenesis is welldocumented. Incontrast,
thedevelopmentofDNAadducts intheN7 positionmight not
have contentvalidity as amarkerofbiologically effective dose
ifthe06methylguanineadductisshowntobethatwhichismost
clearly relatedtothe carcnogenic process. However, theN7ad-
ductsmightbereasonably validmarkersofBaPbiologically ef-
fectivedoseiftheproductionof06andN7adducts aredirectly
proportional(aswouldbeexpectedifthey wereproducedbythe
same activated BaP metabolite), and ifrelatively little time is
allowedforpossibledifferentialrepair(orthelikelyeffectofdif-
ferentialrepaironthemeasurementisremovedduringextrapola-
tionofthe data to 0time).
Toproperly assess contentvalidity, onemustconsiderthe ex-
tenttowhichthemarkerpertainstothephenomenon(exposure,
effect) ofinterest or, the extent to whichthemarker represents
a relevant feature ofthatphenomenon. Forexample, ifit were
assumedthathydroxyethylhistidineadductsofhemoglobin were
markersoftheinternaldoseofethyleneoxide, thatmarkerwould
lackcomplete contentvalidity sincehydroxyethyl histidinead-
ductsofhemoglobin canresultfromexposuretoothersubstans
that contain ethyl groups. Furthermore, populations with no
known exposure to ethylene oxide have been shown to form
hydroxyethyl histidine adductsofhemoglobin. Withoutconsider-
ing contentvalidity, onemightreach erroneousconclusions ifit
wereassumedthatonly ethyleneoxide exposure wasresponsi-
blefortheobservedadducts. alidmeasuresmightbedeveloped
bysubtractingtheamountofadductsattributable tofactorsother
thantheexposureunderstudyfromthetotalamountsofadducts
formed. This requires the evaluation of a nonexposed com-
parison group.
Because content validity is assessed by professional judg-
ment,therearenouniversallyacceptedcriteriaforitsdewemina-
tion(1). However, itispossibletostrengthendeterminationsof
contentvalidityifjudgmentsaremadebyagroupofexperts. The
focus of such judgments should be the degree to which the
marker represents the underlying phenomenon. Establishing
content validity is especially difficult in situations where it is
mostneeded, i.e., wherethereisanincompleteunderstanding
of the domain of underlying characteristics of the exposure-
diseaseprocess.
ConstructValidity
Constructvaliditydescribestheextenttowhichamarkercor-
responds to other relevant characteristics of the underlying
phenomenon, thatis, thetheoreticalconceptsorconstructscon-
cerningthephenomenonunderstudy(9). Thiscorrespondence
isexhibitedinpartbyassociationofthesubjectmarkerwithother
markersorvariablesofthephenomenon (12,13). Forexample,
ifthecharacteristicsofaphenomenonchangewithage, amarker
with construct validity will change accordingly (9). Further-
more, iftherearenoassociationswithothervariablesthatwould
reasonablybeexpectedtobelinked withthephenomenonunder
study, then the marker may be ofquestionable relevance in a
study orsubsequent riskassessment.
Constructvalidity is sometimesdifficulttodistinguish from
content validity when describing biological markers, but it
should be evaluated whenever general understanding of the
underlyingphenomenonisnotclear. Hence,ifamarkerisacan-
didateforinclusioninastudyofanexposureoroutcome, andthe
actalroleofthemarkerintheexposure-outcomecontinuumhas
not been established (that is, its content validity has not been
established), itstillmaybeusefulasacovariateifitcanbeshown
tohaveconstructvalidity.
CriterionValidity
Criterionvaliditydescribestheextenttowhichamarkercor-
relateswiththephenomenonbeingstudied(9). Forexample,the
criterionvalidityofamarkerofdiseaseistheextenttowhichpeo-
plewhohavethemarkeralreadyhaveorwilldevelopthedisease.
Thecriterioniswhatisbeingmarkedorindicatedbythemarker;
generally this is adisease, butitcouldalsobe anexposure.
1\oaspectsofcriterionvalidityhavebeendistinguished,con-
currentvalidityandpredictivevalidity(9). Whenamarkerand
itscriterionrefertothesamepointintime,theyhaveconcurrent
validity. Forexample, abiologicalmarkerofexposure, suchas
ahemoglobinadduct, is validatedagainstadetermination ofa
DNAadductinatargetorgan(iftheyoccursimultaneously). Por
markers of exposure, concurrent validity is satisfied by
understanding the stoichiometric relationship betweenthe ex-
posure and the internal or biologically effective dose. For
markersofeflfct, concurrentvalidityissatisfiedbyastrongcor-
relationbetweenthemarkerandthediseaseordysfuionofin-
terest. Concurrent validity is usually determined in cross-
sectional studies.
Predictive validity refers to a marker's ability to predict the
criterion (9). For example, a marker ofaltered structure and
function, suchasabnormalsputumcytology, couldbevalidated
against subsequent diagnostic confirmation oflung cancer.
Predictive validation requires obtaining samples of subjects,
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measuring somemarker, waitingthenecessary timefortheef-
fect(criterion)tooccur, thenassessingtheobservedcorrelation
(10,14). Otherfactorstoconsiderinpredictivevalidationmight
include intervening ormodifying characteristics thatcould in-
fluencetheoccurrenceoftheendpointandstochasticeffectsin
thedevelopmentoftheoutcomecriterion. Ingeneral, thedegree
ofpredictivevaliditydependsontheextentofthecorrelationbet-
weenthemarkerandthecriterion. Predictivevalidityappliesto
markers ofexposure, effect, or susceptibility.
Predictive validation isperformedusing alongitudinal (pro-
spective) studydesign. Sinceoneofthedrawbacksinassessing
predictivevalidity isthepotentially longtimecoursenecessary
forthedevelopmentofthecriterion, therearetime-compressing
studydesignsthatareuseful. Oneisthecontemporaneouscase-
control design and another is the retrospective case-control
design; botharelimitedintheirabilitytoassessmarkervalidity.
A contemporaneous case-control design involves obtaining
samples ofindividuals withandwithoutthecriterionofinterest
(i.e., adisease) thenassessing thoseindividuals forthepresence
ofamarker. The spectivecase-controldesigninvolvesselec-
ting individuals with and without a disease (the criterion) and
thenattemptingto identify marker statuspriortotheappearance
ofthe disease or study end date. Clearly, these approaches are
limited. A contemporaneous case-control study, using markers
ofexposure, will notprovide anunambiguous answerconcern-
ing predictability if it is difficult to tell whether the marker
predicts the criterion disease or is merely the result ofit. The
retrospectivecase-control study isdifficulttoperformbecause
itisnoteasy tofindhistoricinfonnationonthepresenceofmany
markers.
Itispossible tojudgethecriterionvalidityofamarkerinterms
ofits sensitivity, specificity, andpredictive value. Griffith etal.
(15) have distinguished the terms sensitivity and specificity as
they-refertolaboratory methods todetectamarkerand as they
areusedtodescribetheability ofamarkertodetectanexposure
or to detect orpredict anevent inapopulation:
Laborayorysedtvttnrderea methersabiityofadetec-
tionsystemtorespondinthepreseneofthemarker. Ppuationsen-
stvty, mconrba, istheSoofnumn ofsubjectspositiveforboth
themarker and the event to the numberofsubjects with the event.
Laboratory specificity refers to thedetection system's ability to fail
torespond intheabsenceofthe marker. Pbplation specificity is the
ratioofthenumberofsubjectsthatarenegative fbrboththe marker
and theevent, tothenumberofsubjectsthatarenegativefortheevent
(15).
Griffith etal. also identified two study designsthatareuseful
fordeterminingpopulationsensitivity andspecificity (15): The
first is based on two independent samples offixed size. In this
design, the health status or exposure status of each subject is
ascertinedandobservations arecollecteduntil thepre-set sam-
ple sizesarereachedineachgroup. Neitherthemarkerfrequen-
cynorthediseasefrequency play arole. Thedatamightbecol-
lected as subjectsareidentified or in acase-control study from
medical records. Also, archivedbiological samplesmightbeus-
ed. Thesecondapproachistoselectasinglesampleoffixedsize
fromthepopulationofinterest, andtodistributethesubjectsinto
a four-fold table according to the presence or absence of the
marker, andthepresenceorabsenceoftheexposureordisease.
Sensitivity isthenestimatedastheratioofthenumberofsubjects
positive for both the marker and the disease to the number of
subjectswiththedisease. Specificityisestimatedistheratioof
subjectsnegativeforboththemarkerandthediseasetothesub-
jectsnegative forthedisease.
Thebestway ofappraising criterion validity istocompare a
markerwithacriterion selectedasthetruecharacteristic oras
the "gold standard" (12,16). This is exemplified by efforts to
determine the validity of a new procedure for determining
whethermalignantorpremaignantbladdercellscanbe
by assessing DNA hyperploidy (17). IfDNA hyperploidy is a
validmarkerofbladdercancer, hyperploidy shouldoccurprior
tovisiblemorphologicalchange, whichisroutinelyevaluatedby
Papanicolaoucytology. Therefore, appropriate validationofthe
markerisnotagainstthecytology, butagainstapositivebladder
biopsy (the gold stndard) sometime inthe future.
Inepidemiologic studies, markersthatareinvalidmeasuresof
aphenomenon canresultinmisclassificationofexposure, effect,
orsusceptibility. AsHogueandBrewster(3)observed, "Anex-
posurevariablemaybemisclassifiedifthemarkerofexposure
hasasensitivityorspecificitylessthan 1.0. Thatis, someonewho
istruly exposed isclassified asbeing notexposed, orsomeone
whoistruly notexposedisclassifiedasbeingexposed." If, for
example, amarkerofbiologically effectivedoseisthebasisfor
exposure classification, misclassification will occur if that
markerdoes notcorrespondtotheactualamountofxenobiotic
that interacts with critical macromolecules. This could occur
withcertainDNAadductsiftheamountthatpersistsisaffected
bytherepairrtesandiftherepairratevariesamong individuals.
In summary, the quality ofriskassessments depends on the
quality andvalidity ofmeasurements. AsMatamoski (18)observ-
ed, "Ifepidemiologists are to address problems ficed by risk
assessors, they must design studies, measure exposures and
analyzeresultswithaconsideredviewofthis specificuse. This
will require newperspectives onthemeasurementofexposures
such as biomarkers and better methods for estimating
exposures."' Withregardtothedesignofstudies, thereisaneed
to use valid markers if the studies are to be of value in risk
assessments.
TheOfficeofTechnologyAssessment(19)alsorecognizedthis
problem:
It is generally not possible to gather reliable information about a
population and concurrently gather validatg information about a
markerusedtomeureoutcom, unlessanotermakerwithknown
validity, and aknown relationship to the newmarker is also used in
the study. Eventhough that istechnically feasible, itisprobably not
anefficient way togatier validating data. (19)
Reliability
Marker validity is also dependant on reliability; that is,, the
degreetowhichamarkerwillbeavalidrepresentativeorpredic-
torofan event is influenced by the reliability witiwhich it can
bemeasured. Reliability encompassesdeunsystnatic, random
variation observed upon repeated measurements (9,22). In the
measurement of continuous variables, such as with most
biological m s, errorsofvariouskinds areinevitable, andthe
absolutely correct measurement nevercanbedetermined (20).
If a measure of a biological marker yields results that differ
markedly from one occasion to another, it is of little value in
research or quantitative risk assessment.
Itispossibletousequantitativeindicesoftheextentofrandom
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variation ofabiologicalmarker. These indices can be used to
determinewhetherthereliability ofagivenmeasureissufficient
forthepurposebeingconsidered. Thetwo mostcomnonindices
are the standard error of the measurement and the reliability
coefficient (20). To assess random errors, multiple measure-
mentsareneededtocompensate forthefactthattherandomer-
ror inthearithmetic meanofseveral measurements islikely to
be much less than the random error in an individual measure-
ment (20). In most epidemiologic research using biologic
markers, there are seldom large numbers ofindividual values.
Thus, onlyasmallnumberofindividualscanbeusedasasam-
ple ofthe infinitely largerpopulation to which thedistribution
refers. The sundard error indicates how the meanofthat sam-
ple is distributed around the mean of the larger population.
Hence, thestandarderrorofthemeanreflects thereliability of
the sample mean as an indicator ofthe population mean (20).
This may notbeas informative asthe reliability coefficient for
evaluating markers to beused in riskassessments.
Thereliabilitycoefficientistechnicallyknownastheintraclass
coefficient of variability (21) and ranges from 0 to 1. If each
measurement is identical, then theintraclass coefficient is 1.0.
The greater the variation between measurements, the less the
reliability. Fleiss(21) hasevaluated theimpactofunsystematic
variation inmeasurement, describedtheuntowardconsequences
unreliability, and recommended howunreliability canbe con-
trolled. TheuntowardconsequencesdescribedbyFleissinclude:
theneedtoincreasesamplesizestoovercomeunreliability; the
systematic biased reduction of correlations between a health
measureandthemeasuredextentofexposuretoanenvironmen-
talriskfactor; andhighratesofmisclassificationincase-control
studiesoftheassociationbetweenexposureanddisease(20). All
ofthesepertaintostudiesusingbiologicmarkersofexposureor
effect. Fleiss(21)recommendsthatunreliabilitybecontrolledby
conducting pilot studies and replicating measurement pro-
ceduresoneachstudy subject. Insomecasesthemeasurement
oftheamount ofa marker is not an end in itselfbut is used to
calculatesomeothervalue,therebypropagatingmeasurementer-
rors(20).Sincecorrectvaluesfrommeasurementsaregenerally
neverknown,calculationswill,perforce,involveerrors. Thus,it
isusefultoknowhowerrorsinindividualmeasurementsaffectthe
resultsofsubsequentcalculations (20). Forexample, individual
errors in a sum or difference ofmeasurements are added and
standarderrorsarecombinedwiththerootsumofsquares (20).
Acknowledgmentofthesecalculation errors should beinclud-
edinstudiesandsubsequentriskassessments. Whensucherrors
become significant, appropriate adjustments shouldbe made.
Internal Study Validity
Anotherbuildingblockofquantitative riskassessment isthe
studyfromwhichinferencesabouttheassociationbetweenex-
posure and effect are drawn. Last (9) has defined the intenal
validityofastudyasthedegreetowhichindexandcomparison
groupsareselectedandcompared sothat, apartfromsampling
errors, theobservedd ;iffrnce betweenthedependentvariables
areattributedonlytothehypothesizedeffect. Thisisvalidity in
theestimationofeffect, anditisdependentontheabilitytocon-
trol bias. Internal study validity has been widely discussed in
epidemiologicaltextbooks. Hence, inthissectionwewilldiscuss
someissuesofinternalvaliditythatpertaintotheuseofbiological
markers.Someoftiisdiscussionisspecificiormarkers,butthiere
areothergeneralissuesthatalsomeritcomment.
Biasisadistortionthatmayresultwhenevaluating anassocia-
tionandcanoccurwhensubject selectionisunequalaccording
todiseaseorexposurestatus. Inselecfing subjects forstudies in-
volvingbiologicmarkers, itisnecessarytoidentifyfactors such
asbackgroundratesofmarkersandtherangeofnormal variables
so that classification and subject selection are equal for the
groups being compared. These issues have been discussed
elsewhere(5,7). Bias can also result from misclassification of
subjects based onexposure or disease and failure to adjust for
othervariablesthatarealsopredictiveofthediseaseofinterest.
Misclassification
Differential misclassification of exposure or disease can
reducethevalidityofastudy(3,7). Biologicmarkers thatallow
for the reduction of misclassification enhance study validity.
Similarly, biologic markers can contribute to the reduction of
nondifferentialmisclassification. Thistypeofmisclassification,
whichhasbeenconsideredalesserthreattovalidity, can result
inbias toward thenull value (22).
Thekeytovalidepidemiologic studiesand,hence,validquan-
titativeriskassessment, isastrongrationaleforselectionofthe
exposure(dose)variables. Thechoiceofexposurevariables for
individuals exposed to toxic substances can range from
anamnestic information gathered by questionnaire to detailed
measurementofbiologicalmarkers(23).However,asRogan(23)
notes,".. . inthe strict sense, any exposureinformation other
thanbiologicaleffectivedoseisasurrogate." Thus, thequestion
ishowcloselydoestheexposuresurrogateusedtoderiveamodel
resemble the actual exposure under study. Valid biological
markerscanprovideempiricaldata, whichareprrenil tothe
useofdeductively derivedestimates (23).
For example, Lawrence and Taylor (24) demonstrated the
valueofempiricalexposuremeasurementswhentheywerecon-
frontedwiththeproblemofassessinghistoricalPCBexposures
ofwomenwhomanufture electricalcapacitors. Thepurpose
oftheirinvestigation was to determine the effects ofPCB ex-
posureonthewomen'sreproductiveoutcomesduringtheperiod
1979to 1983.Thoughtheinvestigatorsdidnothaveactual serum
PCB measurements for thatperiod, they did have a complete
workhistory for each subject and industrial hygiene data that
allowedclassificationofeachjobintermsofalow, medium, or
highconcentation.Thechallengewastochooseasurrogatethat
bestapproximatedthetrueexposure. Theinvestigators alsohad
serathathadbeengatheredin 1976fromasampleofworkersas
apart ofageneral company survey. Using those data, the in-
vestigatorsdevelopedaregressionmodeltoesimate theexplicit
serumPCBconcentrationasacontinuousvariablelevel foreach
womanduringeachofherpregnanciesbetween1979and 1983.
Hence, theserumPCBconcentrations, derived from a sample
ofsubjects, wasusedasabiologicmarkertoconstructamoreac-
curateestimateofthetrueexposurethanwasavailableusingjob
classification data.
AnalyticalAdjustment for OtherVariables
Whentherearemultiplevariablestobeconsideredinastudy,
proper data analysis depends on the choice of the correct
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mathematical model. Thestrongestmodelstakeintoaccounta
priori hypotheses specific to thetopic under study. The incor-
porationofbiologicmarkersinstudydesignsandmathematical
models also implies an understanding of the direction and
mechanismofaction. Additionally, bycontrollingmeasurement
validity, itisalsopossibletopartiallycontrol study validity, as
measurementerrorscanproducebiasedestimatesofregression
coefficients used in models (25).
Longitudinal studiesthatemploybiologicalmarkerswillfind
increasing use inquantitative riskassessments. Thevalidityof
those study results will depend, in part, on the analytical ap-
proachselected. Suchstudiesmayinvolverepeatedmeasuresof
acontinuousrandomvariable. Thus,theremaybemeasurement
errorsthatareconsideredrandombetweenpersons, butwhich
are autocorrelated within persons. The use ofautoregressive
modelingfortheanalysisoflongitudinaldatabyepidemiologists
isincreasingandislikelytobeusedmorefrequentlyinstudies
involvingbiologicalmarkers. Thesemodelsallowforthetreat-
ment of the time course of change of a variable (26). Other
methodsforanalyzingrepetitivemeasuresthatassumeaGaus-
sianerrorstructurehavebeenreviewedbyLouis(25), whocon-
cludedthatthisareaneedscontinuedstatistical, numerical, and
interpretive research anddevelopment.
External Validity
Riskassessmentisanefforttoaddressaconditionofincom-
pletedata (27). Hence, riskassessmentinvolvestheextrapola-
tion(orgeneralization) fromknownexposure-response datato
Hi-definedrisksituations intargetpopulations. Externalvalidity
isthedegreetowhich astudycanproduceunbiasedinferences
about those target populations. For risk assessment, external
validity involves the appropriateness ofextrapolating between
populations orspecies; fromhighdoses tolow doses; andbet-
weendifferentorgans within aspecies. All oftheseefforts can
beenhancedbyusingbiologicmarkerscommontoeachpopula-
tion or species. Allometric assessments ofeffects in different
species canbedeterminedby observing how the samemarker
varies with similar exposures. Valid extrapolation requires an
understanding ofthemajoreventsthatcancausesuchinter-and
intraspeciesdifferences. Forexample, inchemicalcarcinogene-
sis, thefollowingfactorsappeartoplayacriticalroleinspecies
andorgandifferences: theoverall balanceofmetabolicactiva-
tionanddetoxification; thebalanceofDNAdamageandrepair;
thepersistence ofDNAdamage; andtumorformation (28).
There aremany uncertainties attendant to extrapolating to a
largepopulation fromdataderivedfromanepidemiologicstudy
ofasmallergroup. Thecharacteristics thatmakeastudy inter-
nallyvalidareoftenbarrierstoextrapolation. Extrapolationis,
nevertheless, current practice in risk assessment. Using valid
biologicalmarkersmayallowsomeevaluationofwhetherapar-
ticularextrapolation iswarranted; thevariability istooextreme;
or if differences in susceptibility have resulted in sensitive
subgroups (27).
Extrapolationtolowdoses(orexposures)involvesdetermin-
ing (or assuming) the shape of the dose-response curve.
Establishing adose-response relationship in ariskassessment
might be considered a meta analytic procedure in some in-
stnces. Thatis,resultsfromdifferentstudiesmightbecombined
toprovide alargersample size orabroaderrangeofdoseesti-
mates. The validity ofthis effort can be enhanced ifthe same
markers areusedindifferentstudiesorifdifferentmarkershave
been shown tobecorrelated (i.e., haveconstructvalidity).
Thecontributionofmacromolecularadductstolow-doseex-
trapolationhasbeenthemostheraldedpotentialimprovementto
riskassessment. However, theuseofbiologicmarkersalsocan
beasourceofconfusioninriskassessments. Mostofthestudies
ofadducts in humans have not yet demonstrated a clear dose
response(1,29). Thismaybeduetothewidevariabilityinhuman
responseandthecurrentinability to determinetrueindividual
exposures. Untilthesourcesofvariabilitycanbeidentifiedand
theirimpactevaluated, theabsenceorfaultycharacterizationof
adose-responsewilllimittheusefulnessofthisclassofbiologic
markersinriskassessments (30,31). Apotentiallymajorsource
ofdifferential susceptibility indoseresponseisthephenotypic
variationofmetabolicparameters (30). Rarelyhasthisvariation
beenconsidered in riskassessments.
Theeffectofthechoiceofadosevariableonriskestimatescan
be severe, especially when the pattern of exposure that the
esimatesarethoughttoreflectdiffersfromthepredominantpat-
ternexperiencedbyastudycohort(32). Theuseofabiological
markerofexposurecanhelpreducetheimpactofusinganam-
biguousdosevariablebecauseitcanmoreaccuratelyreflectthe
truedose, eveninstudieswhereexposuresareobservedtohave
occurred over a wide range. For example, attempts have been
madetocomparebiologicallyeffectivedosesathighexposures
where tumors are observed to low exposure concentrations to
determinewhetherlinearityofthecarcinogeniceffectisavalid
assumption. Perera(1,29)hasconcludedthatextensivedataon
DNA, RNA, andproteinbindingindicatethatmacromolecular
effects, atthelowestadministereddoses, generallyfollowfirst-
orderkinetics(i.e., therateofbindingintargetorgansinvivois
directly proportional to administered dose). Since many car-
cinogenscovalentlybindto, andstructurallyalterDNA,thead-
ductsthatareformedareconceptuallyvalidmarkersofexposure
and possibly ofeffects. Moreover, the ratio of surrogates for
DNAadducts, suchasproteinadducts, todosehavebeenshown
tobeconstantoveradoserangeof10-'mole/kg to 10 mole/kg
(28,33). However, asSwenberg(34)asked, .... .whatdatabases
areavailablesothatsuchamoleculardosimetryapproachcanbe
validated?" Fewcarcinogenshavebeenevaluatedforwhichthe
exposure range is morethan oneorderofmagnitude (34).
Examplesof Using Biologic Markers
in RiskAssessment
Thetheoretical discussionofmarkervalidity canbeapplied
toriskassessmentsconcerning thefimigantand fueladditive,
ethylene dibromide (EDB) and the sterilant and chemical in-
termediate, ethyleneoxide(EtO). Examinationofthedatacon-
cerningthesetwosubstancesandtheirrelationshiptothedisease
process can provide some insight into the question ofmarker
validity. Thisexaminationissummarized inTable 1. Aswillbe
seenfromthefollowingdiscussion, whatappearstobe avalid
markerofEDBexposureandconsequentdiseaseriskturnsout
to be valid only at high exposures. The data concerning EtO,
however,providesreasonforoptimismthatselectionoftheap-
propriatebiological markercanprovideamorepreciseestimate
ofexposure-response atlowdosesand, therefore, risk.
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Ible 1.Aspet fvaldfty in cancerrisk ass sof
ethykenebromine (EDB) andetdleneaide(EtO).
EDB, EtO,
Validity type bromine release hemoglobinalkylation
Measurement
Content Notvalid overwiderange Validoverwiderangeof
ofexposures exposures
Construct Associationonly with Associationwithacuteand
acute toxicology chronictoxicology
Criterion Notrelated tocancer Related togenotoxicity
Reliability Measure is reproducible Measure isreproducible
Internal study Brrelease relatedtoacute Associated with exposure
response
External PRorsurrogateofcancer Goodsunrgat ofcancer
biologically effective biologicallyefiective
dose dose
Usefulness in Canoverestimate exposure Bettermeasureofairborne
quantitative risk response leading to exposureandbiological-
assessment underestimateoftrue lyeffectivedose.
exposure-response
relationship
BromineRelease inEthyleneDibromide Toxicity
In 1977, whenthe National Institute forOccupational Safety
andHealth recommendedstandards foroccupational exposure
toEDB, it wasestablishedthatEDBcausedmutationsinfungi,
plants, bacteria, insects, and mammalian cell systems, andthat
itinduced cancer in several mammalian species (35). Thedata
presented in that criteria document described several
biochemical eventsthatallowedinvestigators toestimatethein-
ternal doseofEDB.
First, asEDB wasabsorbed, glutathioneproductioninitially
decreased, but then recovered. The decrease in the amount of
glutathione wasassociatedwiththereleaseof2molesofbromine
foreverymoleofglutathionethatdisappeared. Theproduction
offreebrominecouldbecorrelatedtotheairborneexposurecon-
centration, providing anindicationofdose. Furthereviencewas
provided to show that the production of S,S'-ethylene-
bis(glutathione) was saturable (35). More recentdataindicates
that whenthe first molecule ofglutathione reacts with EDB, it
can form a three-membered sulfur-containing ring that can
alkylateDNA toform S-[2-(N7-guanyl) ethyl] glutathione. This
alkylation can occurpriortothedetoxification reactionofEDB
with the secondmoleculeofglutathione (36).
Thesesimpledataoffer someinsightintothe ovell relation-
shipbetweenEDB exposureand cancerdevelopment. Thefact
that the detoxification pathway is only one of the metabolic
pathways indicatesthatdetoxification removesonly aportionof
theEDBfromthesystem, theremainderbeingavailableforreac-
tion with cellular macromolecules. Second, it is possible that
EDB does not react with cellular macromolecules until the
detoxification pathway has become saturated. If this latter
scenario isadopted, thenconsideration mustbegivento the ex-
istenceofathresholdofexposure. Thefirstchoice, ontheother
hand, providessupportfortheconceptthatthereisnodteshold.
Data from other species clearly show that EDB alkylates
macromolecules and causesmutations, evenatdoseswellbelow
thosethat saturatethedetoxificationpatdway, lending supportto
the theory that there is no threshold for the carcinogenic
response. Finally, theproductionoftumorsappearstoberelated
to the cumulative dose (i.e., the exposure concentration
multipliedbythedurationofexposure).
Ifthequantitativerelationshipsbetweenexposureconcentra-
tion,exposureduration,bromineproduction, adductformation,
genemutation, andtumorexpressionwereunderstood, thenit
wouldbefeasibletousebromineproductionasamarkerofin-
creasedcancerriskformeasuresofbrominepriortosaturation
ofthepathway. Doestheinformationaboutbromineproduction
makesenseinthecontextofEDBinducedcancer?Cainlythe
information makessense, atleastqualitatively. EDBisusedas
afueladditivebecauseitsbifunctionalityisexploitedtoremove
excessleadfromengines(7). Itisthatsamereative that
allowsEDBtoactasabifuncionalalkylatorofmacromolecules.
WhenthealkylationofDNAoccurs, thecellattemptstorepair
thedamage. Iftherateofrepairislessthantherateofalkylation,
thenthedamagepersistsandcanleadtoavarietyofunwwardef-
fects. Theobservationofenhanced DNA repair rates inmam-
malian systemssupportsthismechanism. However, itisimpor-
tanttonotethattheinitial studiesonbromineproductionwere
conductedathigh, int icdosesthatsaedthemetabolic
detoxificationmechanisms (35).
OtherstudiesinwhichanimalswereexposedtoEDBinairat
lowerconcentrations indicatedthattherateofmetabolismwas
about 100timesgreaterthantherateofabsorption, andthusex-
posureby inhalationmay notposethesamethreatasexposure
by other routes such as feedingorgavage (35). Subsequent in-
halation studies revealed that inhalation exposures at 10 ppm
resultedintumordevelopmentinmammals (35). Basedonphar-
macokineticdata,anexposureat 10ppmwouldresultintheab-
sorptionofaslittleas0.4IsmoleEDB/Lofair, aconcentration
well below that shown to saturate detoxification mechanisms
(35). These data indicate that EDB can exert its efect in two
ways: by direct action on the tissues that it contacts; and
systemically. Thelattermechanismindicatesthatnormaldetox-
ification mechanisms do not adequately remove all the EDB,
evenatrelativelylowdoses.Basedonthisinformation,itappears
thatbromineproduction, whilequalitatively consistentwith a
possible carcinogenic mechanism, is not a good quantitative
markerforEDB-inducedcarcinogenesis.
Inordertoobtainmorepreciseinformationontherelationship
between EDB exposure and cancer induction, amarker more
sensitivetocellularactivitythinbrominereleaseisneeded. One
suchmarkermightbetheformationEDB-DNAadducts, oras
appears to be the case for EtO, the formation ofhemoglobin
adducts.
HemogloblinAlkylationbyEthyleneOxide
Qualitatively, thedataconcerningthetoxicityofEtOparallels
thatofEDB. Eachofthosechemicals isacutelytoxic. EtOand
EDBcancausemutationsinavarietyofplant,bacterial, insect,
andmanummaianspeciesbothinvitroandinvvo, andanumber
ofinvestigatorshaveclearlyestablishedtherelationshipbetween
EtOexposureandalkylationofhemoglobin, DNA, andcancer
development. For example, Burgnone et al. (37) have
demonstratedthattheextentofinvivohemoglobinalkylationis
proportionaltotheairborneconcentrationofEtOandthecon-
centration of EtO in blood. Calleman et al. (38,39) and
Ostennan-Golkar (40) have shown that the amount ofEtO in
blood is proportional to the formation ofDNA adducts. In a
relatedstudy, Yager(41)hasdemonstratedthatthefrequencyof
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sisterchromatidexchange inperipheral bloodofEtO-exposed
workers is proportional to cumulative dose (i.e., ppm x hr).
Finally, Callemanetal. hasshownthatthereisarelationshipbe-
tween the extent of hemoglobin alkylation by EtO and the
numberofratswithtumorsfollowinginhalationexposuretoEtO
(38,39). Callemanusedthosedatatoesfimatetheriskofdevelop-
ing leukemiaasaresultofEtOexposure(38,39).
ItisclearthattheformationofalkylatedhemoglobinbyEtO
satisfiestherequirementsofavalidbiological marker. Though
thefonnationofthatparticularmarkerappearstobeaneventthat
occurs independent of those related to EtO-induced cancer
development, theformationofhemoglobinadductsbyEtOap-
pearstobeagoodsurrogateforpredictingrisk. Thisconclusion
is based ontheassumption thatothermammalianhemoglobin
wouldrespond similarly, however, thepreciserelationships do
need to be elucidated. These relationships have been demon-
strated in subsequentresearch (42,43).
Conclusion
Theframeworkpresentedhereandinapreviouspaper(6)may
serveasabasisforevaluatingthevalidityofbiologicalmarkers
for research and forquantitative riskassessments. Atpresent,
therearefewvalidbiologicalmarkersthatcanbeusedtoconduct
quantitative riskassessments. Beforeamarkerisuseful inrisk
assessment, it should be showntohavecontent, criterion, and
construct validity, and it should be shown to be reliable. Pilot
studies shouldbeperformedtoestablishbackgroundlevels, the
rangeofnormal,confoundingfactors, andoptinulcollectionand
analytical techniques. Res hstudiesusingbiological markers
willneedtobeofappropriatesamplesizeandpayattentiontothe
properselectionofsubjectsandtheuseofappropriatestatistical
techniques (5,6).
If studies are to be useful in risk assessment, they must be
generalizable but, more importantly, they must be internally
valid. Hence, tosatisfytheultimateneedforgeneralizabilityand
still be internally valid, studies should involve heterogenous
populationsampleswithhomogenoussubgroupingswithinthe
samples. If separate studies are conducted for use in risk
assessments, effortsshouldbemadetousesimilarmarkersand
topay attention toconfounding factors.
Failuretoconsiderthevalidityofcomponentsofariskassess-
mentcanleadtoerroneousconclusions. Forexample, inthecase
ofEDB, ifattemptsweremadetoconstr riskargumentsbased
onbrominereleasedata, itmighthavebeenconcludedthatthere
is a threshold ofexposure that must be passed before the car-
cinogenic process can be initiated. The EtOdata, ontheother
hand,clearlyshowrelationshipsbetweenairborneexposurecon-
centrations, time, and events at the molecular level that are at
leastindicativeofagenotoxicandcarcinogenicmechanismthat
isconsistentwithgenerallyacceptedtheoriesofcarcinogenicity.
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